Treatment of experimental Pneumocystis carinii pneumonia with 1,3-di(4-imidazolino-2-methoxyphenoxy)propane lactate.
An analogue of pentamidine, 1,3-di(4-imidazolino-2-methoxyphenoxy)propane (DMP) lactate, was tested against rat Pneumocystis carinii pneumonia (PCP). The drug was found to be highly active in the treatment of rat PCP at a dose of 1.75 mg/kg (parent molecule) when administered by intravenous (i.v.) injection (daily for 2 wk). The compound was also active against PCP when given orally, however, significantly higher doses of DMP were necessary when compared to the i.v. dosing regimen. Prophylactic doses (i.v.) of the drug also proved highly effective in preventing PCP.
Tidwell
R R
RR
Department of Pathology, University of North Carolina, Chapel Hill 27599.
Jones
S K
SK
Dykstra
C C
CC
Gorton
L
L
Hall
J E
JE
D000284:Administration, Oral; D000818:Animals; D004305:Dose-Response Relationship, Drug; D006851:Hydrochloric Acid; D007275:Injections, Intravenous; D007773:Lactates; D019344:Lactic Acid; D008168:Lung / Q000382:microbiology; D008297:Male; D015394:Molecular Structure; D010419:Pentamidine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy*; D051381:Rats; D011919:Rats, Inbred Strains
D007773:Lactates; C065258:1,3-di(4-imidazolinophenoxyl)propane; D019344:Lactic Acid; D010419:Pentamidine; D006851:Hydrochloric Acid